Big Biologics Bet: China’s Innovent Gets $100m Financing
This article was originally published in PharmAsia News
Executive Summary
A record-breaking private financing for a Chinese biotech has seen bets placed on Suzhou-based Innovent Bio, which has 10 monoclonal antibodies including four biosimilars in its pipeline.
You may also be interested in...
Behind The First Inhaled COVID Vaccine: Chinese-Language CEO Podcast With CanSino’s Xuefeng Yu
After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.
China Drug Price Negotiations: Another Race To The Bottom？
With the fourth quarter just around the corner, China's closely-watched annual drug reimbursement and prices negotiations are entering a key final stage. But will applicants need to be more strategic than expedient?
China Closes In On Top 10 In Global Innovation Ranking
China is knocking on the door of the world’s top 10 most innovative economies, helped by sustained investment.